Differential molecular mechanism of docetaxel-octreotide combined treatment according to the docetaxel-resistance status in PC3 prostate cancer cells
Posted on 17 dicembre 2014
Lattanzio L, Tonissi F, Monteverde M, Milano G, Merlano MC, Lo Nigro C.
Anticancer Drugs. 2013 Feb;24(2):120-30. doi: 10.1097/CAD.0b013e328358d1dc.